Haase, Detlef

[["dc.bibliographiccitation.firstpage","73483"],["dc.bibliographiccitation.issue","43"],["dc.bibliographiccitation.journal","Oncotarget"],["dc.bibliographiccitation.lastpage","73500"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Orazi, Attilio"],["dc.contributor.author","Steensma, David P."],["dc.contributor.author","Ebert, Benjamin L."],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Malcovati, Luca"],["dc.contributor.author","van de Loosdrecht, Arjan A."],["dc.contributor.author","Haferlach, Torsten"],["dc.contributor.author","Westers, Theresia M."],["dc.contributor.author","Wells, Denise A."],["dc.contributor.author","Giagounidis, Aristoteles"],["dc.contributor.author","Loken, Michael"],["dc.contributor.author","Orfao, Alberto"],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Ganser, Arnold"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Ogata, Kiyoyuki"],["dc.contributor.author","Schanz, Julie"],["dc.contributor.author","Béné, Marie C."],["dc.contributor.author","Hoermann, Gregor"],["dc.contributor.author","Sperr, Wolfgang R."],["dc.contributor.author","Sotlar, Karl"],["dc.contributor.author","Bettelheim, Peter"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Pfeilstöcker, Michael"],["dc.contributor.author","Horny, Hans-Peter"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Greenberg, Peter"],["dc.contributor.author","Bennett, John M."],["dc.date.accessioned","2019-12-17T12:21:04Z"],["dc.date.accessioned","2021-10-27T13:21:59Z"],["dc.date.available","2019-12-17T12:21:04Z"],["dc.date.available","2021-10-27T13:21:59Z"],["dc.date.issued","2017"],["dc.description.abstract","Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms characterized by peripheral cytopenia, dysplasia, and a variable clinical course with about 30% risk to transform to secondary acute myeloid leukemia (AML). In the past 15 years, diagnostic evaluations, prognostication, and treatment of MDS have improved substantially. However, with the discovery of molecular markers and advent of novel targeted therapies, new challenges have emerged in the complex field of MDS. For example, MDS-related molecular lesions may be detectable in healthy individuals and increase in prevalence with age. Other patients exhibit persistent cytopenia of unknown etiology without dysplasia. Although these conditions are potential pre-phases of MDS they may also transform into other bone marrow neoplasms. Recently identified molecular, cytogenetic, and flow-based parameters may add in the delineation and prognostication of these conditions. However, no generally accepted integrated classification and no related criteria are as yet available. In an attempt to address this challenge, an international consensus group discussed these issues in a working conference in July 2016. The outcomes of this conference are summarized in the present article which includes criteria and a proposal for the classification of pre-MDS conditions as well as updated minimal diagnostic criteria of MDS. Moreover, we propose diagnostic standards to delineate between ´normal´, pre-MDS, and MDS. These standards and criteria should facilitate diagnostic and prognostic evaluations in clinical studies as well as in clinical practice."],["dc.identifier.doi","10.18632/oncotarget.19008"],["dc.identifier.eissn","1949-2553"],["dc.identifier.pmid","29088721"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17006"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/92060"],["dc.language.iso","en"],["dc.notes.intern","Migrated from goescholar"],["dc.relation.eissn","1949-2553"],["dc.relation.orgunit","Universitätsmedizin Göttingen"],["dc.rights","CC BY 3.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/3.0"],["dc.subject.ddc","610"],["dc.title","Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","205"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Haematologica"],["dc.bibliographiccitation.lastpage","213"],["dc.bibliographiccitation.volume","100"],["dc.contributor.author","Braulke, Friederike"],["dc.contributor.author","Platzbecker, Uwe"],["dc.contributor.author","Müller-Thomas, Catharina"],["dc.contributor.author","Götze, Katharina"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Brümmendorf, Tim H."],["dc.contributor.author","Nolte, Florian"],["dc.contributor.author","Hofmann, Wolf-Karsten"],["dc.contributor.author","Giagounidis, Aristoteles A. N."],["dc.contributor.author","Lübbert, Michael"],["dc.contributor.author","Greenberg, Peter L."],["dc.contributor.author","Bennett, John M."],["dc.contributor.author","Solé, Francesc"],["dc.contributor.author","Mallo, Mar"],["dc.contributor.author","Slovak, Marilyn L."],["dc.contributor.author","Ohyashiki, Kazuma"],["dc.contributor.author","Le Beau, Michelle M."],["dc.contributor.author","Tüchler, Heinz"],["dc.contributor.author","Pfeilstöcker, Michael"],["dc.contributor.author","Nösslinger, Thomas"],["dc.contributor.author","Hildebrandt, Barbara"],["dc.contributor.author","Shirneshan, Katayoon"],["dc.contributor.author","Aul, Carlo"],["dc.contributor.author","Stauder, Reinhard"],["dc.contributor.author","Sperr, Wolfgang R."],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","Fonatsch, Christa"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Schanz, Julie"],["dc.date.accessioned","2019-07-09T11:41:10Z"],["dc.date.available","2019-07-09T11:41:10Z"],["dc.date.issued","2015-02-01"],["dc.description.abstract","International Prognostic Scoring Systems are used to determine the individual risk profile of myelodysplastic syndrome patients. For the assessment of International Prognostic Scoring Systems, an adequate chromosome banding analysis of the bone marrow is essential. Cytogenetic information is not available for a substantial number of patients (5%-20%) with dry marrow or an insufficient number of metaphase cells. For these patients, a valid risk classification is impossible. In the study presented here, the International Prognostic Scoring Systems were validated based on fluorescence in situ hybridization analyses using extended probe panels applied to cluster of differentiation 34 positive (CD34(+)) peripheral blood cells of 328 MDS patients of our prospective multicenter German diagnostic study and compared to chromosome banding results of 2902 previously published patients with myelodysplastic syndromes. For cytogenetic risk classification by fluorescence in situ hybridization analyses of CD34(+) peripheral blood cells, the groups differed significantly for overall and leukemia-free survival by uni- and multivariate analyses without discrepancies between treated and untreated patients. Including cytogenetic data of fluorescence in situ hybridization analyses of peripheral CD34(+) blood cells (instead of bone marrow banding analysis) into the complete International Prognostic Scoring System assessment, the prognostic risk groups separated significantly for overall and leukemia-free survival. Our data show that a reliable stratification to the risk groups of the International Prognostic Scoring Systems is possible from peripheral blood in patients with missing chromosome banding analysis by using a comprehensive probe panel (clinicaltrials.gov identifier:01355913)."],["dc.identifier.doi","10.3324/haematol.2014.110452"],["dc.identifier.pmid","25344522"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11765"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/58365"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1592-8721"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1124"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","HAEMATOLOGICA-THE HEMATOLOGY JOURNAL"],["dc.bibliographiccitation.lastpage","1134"],["dc.bibliographiccitation.volume","94"],["dc.contributor.author","van de Loosdrecht, Arjan A."],["dc.contributor.author","Alhan, Canan"],["dc.contributor.author","Bene, Marie Christine"],["dc.contributor.author","Della Porta, Matteo Giovanni"],["dc.contributor.author","Drager, Angelika M."],["dc.contributor.author","Feuillard, Jean"],["dc.contributor.author","Font, Patricia"],["dc.contributor.author","Germing, Ulrich"],["dc.contributor.author","Haase, Detlef"],["dc.contributor.author","Homburg, Christa H."],["dc.contributor.author","Ireland, Robin"],["dc.contributor.author","Jansen, Joop H."],["dc.contributor.author","Kern, Wolfgang"],["dc.contributor.author","Malcovati, Luca"],["dc.contributor.author","Marvelde, Jeroen G. Te"],["dc.contributor.author","Mufti, Ghulam J."],["dc.contributor.author","Ogata, Kiyoyuki"],["dc.contributor.author","Orfao, Alberto"],["dc.contributor.author","Ossenkoppele, Gert J."],["dc.contributor.author","Porwit, Anna"],["dc.contributor.author","Preijers, Frank W."],["dc.contributor.author","Richards, Stephen J."],["dc.contributor.author","Schuurhuis, Gerrit Jan"],["dc.contributor.author","Subira, Dolores"],["dc.contributor.author","Valent, Peter"],["dc.contributor.author","van der Velden, Vincent H. J."],["dc.contributor.author","Vyas, Paresh"],["dc.contributor.author","Westra, August H."],["dc.contributor.author","de Witte, Theo M."],["dc.contributor.author","Wells, Denise A."],["dc.contributor.author","Loken, Michael R."],["dc.contributor.author","Westers, Theresia M."],["dc.date.accessioned","2018-11-07T08:27:14Z"],["dc.date.available","2018-11-07T08:27:14Z"],["dc.date.issued","2009"],["dc.description.abstract","The myelodysplastic syndromes are a group of clonal hematopoietic stem cell diseases characterized by cytopenia(s), dysplasia in one or more cell lineages and increased risk of evolution to acute myeloid leukemia (AML). Recent advances in immunophenotyping of hematopoietic progenitor and maturing cells in dysplastic bone marrow point to a useful role for multiparameter Row cytometry (FCM) in the diagnosis and prognostication of myelodysplastic syndromes. In March 2008, representatives from 18 European institutes participated in a European LeukemiaNet (ELN) workshop held in Amsterdam as a first step towards standardization of FCM in myelodysplastic syndromes. Consensus was reached regarding standard methods for cell sampling, handling and processing. The group also defined minimal combinations of antibodies to analyze aberrant immunophenotypes and thus dysplasia. Examples are altered numbers of CD34(+) precursors, aberrant expression of markers on myeloblasts, maturing myeloid cells, monocytes or erythroid precursors and the expression of lineage infidelity markers. When applied in practice, aberrant FCM patterns correlate well with morphology, the subclassification of myelodysplastic syndromes, and prognostic scoring systems. However, the group also concluded that despite strong evidence for an impact of FCM in myelodysplastic syndromes, further (prospective) validation of markers and immunophenotypic patterns are required against control patient groups as well as further standardization in multi-center studies. Standardization of FCM in myelodysplastic syndromes may thus contribute to improved diagnosis and prognostication of myelodysplastic syndromes in the future."],["dc.identifier.doi","10.3324/haematol.2009.005801"],["dc.identifier.isi","000268677200012"],["dc.identifier.pmid","19546437"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5957"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16171"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ferrata Storti Foundation"],["dc.relation.issn","1592-8721"],["dc.relation.issn","0390-6078"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]